Overview

A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy

Status:
Completed

Trial end date:
2015-03-01

Target enrollment:

Participant gender:

Summary

The present pilot study is designed to assess the extent to which rasagiline may improve cognition in Parkinson's disease patients requiring dopaminergic therapy. The primary objective is to assess improvement in the Montreal Cognitive Assessment (MoCA) in patients who have been on rasagiline at 1mg daily for twelve weeks. The secondary objective is to assess changes in the SCOPA-COG, FAB, and UPDRS II & III at the end of week 14.

Phase:

Phase 4

Details

Lead Sponsor:

Georgetown University

Collaborator:

Teva Neuroscience, Inc.

Treatments:

Dopamine
Dopamine Agents
Dopamine Agonists
Rasagiline